Q3 FY2026
Filed Nov 10, 2026Q3 2026 revenue fell 24% to $8.6 million as system sales dropped to 40 units, and the company posted a GAAP operating loss of $1.1 million against operating income a year earlier.
Revenue fell 24% year over year, Ultramist system placements dropped to 40 from 155, GAAP operating income turned to an operating loss, net income turned to a net loss, and Adjusted EBITDA fell to $698 thousand from $3,216 thousand. Applicator revenue grew 2%, and gross margin held near prior levels at 77.3%. No guidance was issued in the filing.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Q3 2026 (GAAP)GAAP | $8.58M | – | -24% |
| Cost of revenues, Q3 2026GAAP | $1.95M | – | – |
| Gross margin ($), Q3 2026GAAP | $6.63M | – | – |
| Gross margin %, Q3 2026GAAP | 77.3% | – | – |
| Total operating expenses, Q3 2026GAAP | $7.70M | – | – |
| General and administrative, Q3 2026GAAP | $5.13M | – | – |
| Selling and marketing, Q3 2026GAAP | $1.87M | – | – |
| Research and development, Q3 2026GAAP | $426K | – | – |
| Depreciation and amortization (operating expense), Q3 2026GAAP | $274K | – | – |
| Operating (loss) income, Q3 2026 (prior-year column is operating income)GAAP | −$1.07M | – | – |
| Interest expense, Q3 2026GAAP | −$276K | – | $1.5 million decrease in interest expense |
| Total other (expense) income, net, Q3 2026GAAP | −$281K | – | – |
| Net (loss) income, Q3 2026GAAP | −$1.42M | – | – |
| Diluted EPS, Q3 2026GAAP | $(0.16) | – | – |
| Basic EPS, Q3 2026GAAP | $(0.16) | – | – |
| Adjusted EBITDA, Q3 2026non-GAAP | $698K | – | – |
| EBITDA, Q3 2026non-GAAP | −$736K | – | – |
| Ultramist systems sold, Q3 2026other | 40 systems | – | – |
| Ultramist applicator revenue, Q3 2026other | $6.9M | – | +2% |
| Cash and cash equivalents, September 30, 2026GAAP | $6.57M | – | – |
| Revenue, nine months 2026 (GAAP)GAAP | $27.94M | – | – |
| Gross margin ($), nine months 2026GAAP | $21.48M | – | – |
| Gross margin %, nine months 2026GAAP | 76.9% | – | – |
| Total operating expenses, nine months 2026GAAP | $23.96M | – | – |
| Operating (loss) income, nine months 2026 (prior-year column is operating income)GAAP | −$2.48M | – | – |
| Interest expense, nine months 2026GAAP | −$1.34M | – | – |
| Net (loss) income, nine months 2026GAAP | −$3.54M | – | – |
| Diluted EPS, nine months 2026GAAP | $(0.41) | – | – |
| Basic EPS, nine months 2026GAAP | $(0.41) | – | – |
| Adjusted EBITDA, nine months 2026non-GAAP | $2.99M | – | – |
| Net cash flows (used in) provided by operating activities, nine months 2026GAAP | −$29K | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Ultramist applicator revenueThe filing prints the revenue and the 2% increase against $6.8 million in Q3 2025. It gives no explanation for this line. | $6.9M | – | +2% |
Capital returns
- The filing reports no share repurchases and no cash dividends for Q3 2026 or the nine months ended September 30, 2026.
- Shares issued and outstanding were 8,602,309 at September 30, 2026, against 8,588,876 at December 31, 2025.
- Stock-based compensation was $1,480 thousand in Q3 2026 (versus $1,397 thousand in Q3 2025) and $4,622 thousand for the nine months 2026 (versus $3,513 thousand for nine months 2025), per the Adjusted EBITDA reconciliation.
- Shares granted in lieu of board of director fees were $103 thousand in Q3 2026.
What drove it
- The company states that Q3 was 'very much the story of the CMS proposed rule.' Per the CEO, the proposal to maintain skin substitute pricing at 2026 levels for 2027 led some mobile wound care practitioners, particularly rural home care providers, to exit some or all of their operations, and this affected a number of the company's customers.
- Per the CEO, proposed changes to the 97610 code produced a 'wait and see' approach across the quarter which, together with an ongoing market for used Ultramist units, had a significant effect on system sales in the quarter.
- The company states the Q3 2026 net loss change was primarily attributable to the absence of a $6.1 million non-cash gain on the change in fair value of derivative liabilities and a one-time $5.0 million gain on the sale of patents, both recognized in the prior-year period, and to an operating loss of $1.1 million against operating income of $0.9 million. The filing says this was partially offset by a $1.5 million decrease in interest expense.
- The company cites as positives a 14% increase in HOPD rates for 97610 and removal of Q1 status from the code, which will allow it to be billed at the same time as other procedures rather than being packaged to zero.
- The company states that CMS and the AMA RUC have signaled interest in the structure of the 97610 code, and that it will seek to encourage and engage with this work.
- The company states it continues to gain traction in hospitals and other users where cost savings by halting wound progression is the primary concern.
- The filing states that 2025 comparative figures in the statements are 'As Restated', and that prior period D&A was retroactively revised to exclude amortization of right-of-use leases, with no effect on U.S. GAAP results.
Concerns
- Ultramist system sales fell to 40 in Q3 2026, against 155 in Q3 2025 and 82 in Q2 2026.
- Revenue fell 24% year over year, and nine-month gross margin declined to 76.9% from 78.2%.
- GAAP operating loss of $(1,072) thousand in Q3 2026 compares with operating income of $903 thousand a year earlier. Nine-month operating loss was $(2,476) thousand against operating income of $2,942 thousand.
- Adjusted EBITDA was $698 thousand in Q3 2026 against $3,216 thousand, and $2,994 thousand for nine months 2026 against $8,722 thousand.
- Operating expenses for the nine months rose to $23,961 thousand from $21,025 thousand while revenue fell to $27,937 thousand from $30,657 thousand.
- Operating cash flow for the nine months was $(29) thousand against $557 thousand (2025 As Restated), and cash fell to $6,569 thousand from $11,959 thousand at December 31, 2025.
- The company paid approximately $2.3 million under sales tax voluntary disclosure agreements during the quarter.
- Forward-looking risks listed by the company include its ability to regain and maintain compliance with Nasdaq listing requirements and to comply with financial and other covenants under its credit agreement with JPMorgan Chase Bank, N.A.
- The filing notes the emergence of a secondary market for used Ultramist systems and states that resales can cannibalize sales of new systems.
What to watch
- Ultramist system placements against the 40 units in Q3 2026 and 82 units in Q2 2026, and whether used-unit resales continue to affect new system sales.
- Finalization of CMS policy on skin substitute pricing for 2027 and any changes to the 97610 code structure, including the Q1 status change and HOPD rate change the company cited.
- Ultramist applicator revenue trend, given the company's statement that it seeks to convert system placements into recurring consumable revenue.
- Operating expense levels, which were $7,701 thousand in Q3 2026, and the path back to positive operating income.
- Cash position, term loan repayments, revolver balance and covenant compliance under the JPMorgan credit agreement.
- Progress on regaining Nasdaq listing compliance, as referenced in the filing's risk factors.
- The business update conference call on November 11, 2026 at 8:30 a.m. EST, where the company has said materials are available on its website.
Balance sheet and cash flow
- Cash and cash equivalents were $6,569 thousand at September 30, 2026, against $11,959 thousand at December 31, 2025. The company states that this figure was affected by approximately $2.3 million paid under its sales tax voluntary disclosure agreements during the quarter.
- Total assets were $32,521 thousand at September 30, 2026, against $37,343 thousand at December 31, 2025.
- Total liabilities were $29,671 thousand at September 30, 2026, against $35,724 thousand at December 31, 2025.
- Total stockholders' equity was $2,850 thousand at September 30, 2026, against $1,619 thousand at December 31, 2025.
- Secured term loan: current portion $5,660 thousand and non-current portion $11,419 thousand at September 30, 2026, against $5,638 thousand and $15,667 thousand at December 31, 2025 (both net of debt issuance costs as printed).
- Secured revolving credit facility: $655 thousand classified as current at September 30, 2026, and $0 non-current, against $655 thousand non-current at December 31, 2025.
- Nine months 2026 cash flows: operating activities $(29) thousand; investing activities $(811) thousand; financing activities $(4,550) thousand; net change in cash $(5,390) thousand.
- Nine months 2026 financing included repayment of principal on the secured term loan of $(4,313) thousand and repayment of the insurance premium financing note of $(315) thousand.
- Nine months 2026 supplemental cash paid for interest was $1,511 thousand, against $3,291 thousand for nine months 2025. Cash paid for taxes was $87 thousand against $0.
- Q3 2026 operating and investing cash flows are not printed separately; only the nine-month cash flow statement is provided.
Analysis
SANUWAVE reported Q3 2026 revenue of $8,579 thousand, down 24% from $11,270 thousand in Q3 2025. The filing attributes the decline in system sales to the CMS proposed rule, as stated by the CEO. Ultramist systems sold fell to 40 from 155 a year earlier and from 82 in Q2 2026. The only revenue line the filing breaks out is Ultramist applicator revenue, which rose 2% to $6.9 million from $6.8 million, so the applicator line was roughly flat while system volumes fell sharply.
Gross margin held at 77.3% against 77.6% in Q3 2025, and gross margin dollars fell to $6,629 thousand from $8,744 thousand. Operating expenses were $7,701 thousand against $7,841 thousand, with general and administrative and selling and marketing both lower and research and development up to $426 thousand from $345 thousand. Because revenue fell faster than costs, the company reported a GAAP operating loss of $(1,072) thousand against operating income of $903 thousand a year earlier. Adjusted EBITDA was $698 thousand against $3,216 thousand.
The Q3 2025 net income of $9,688 thousand included a $6.1 million non-cash gain on the change in fair value of derivative liabilities and a $5.0 million gain on the sale of patents. The company states that the absence of these items, together with the operating loss, was the primary reason net income turned to a net loss of $(1,416) thousand, partly offset by a $1.5 million decrease in interest expense. Basic and diluted EPS were both $(0.16) for Q3 2026, against $1.13 basic and $0.39 diluted in the prior-year quarter.
On a nine-month basis, revenue was $27,937 thousand against $30,657 thousand, gross margin fell to 76.9% from 78.2%, and operating expenses rose to $23,961 thousand from $21,025 thousand. The nine-month operating loss was $(2,476) thousand and the net loss was $(3,537) thousand, against operating income and net income of $2,942 thousand and $4,121 thousand. Operating cash flow was $(29) thousand against $557 thousand (2025 As Restated), and cash ended the period at $6,569 thousand against $11,959 thousand at December 31, 2025, after $4,313 thousand of term loan principal repayments and a payment of about $2.3 million under sales tax voluntary disclosure agreements in the quarter.
The company issued no guidance in this filing. The positives the company cites are the 14% increase in HOPD rates for 97610 and the removal of Q1 status from that code, along with continued interest from CMS and the AMA RUC in the code's structure. Investors should weigh these against the sharp drop in system placements, the used-unit market the company describes, and the risk factors it lists on Nasdaq compliance and credit agreement covenants.
Management, verbatim
Q3 was very much the story of the CMS proposed rule.
Morgan Frank, CEO
The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.
Morgan Frank, CEO
The silver linings in all this were a 14% increase in HOPD (hospital outpatient department) rates for 97610 and a removal of Q1 status from the code which will allow it to be billed at the same time as other procedures rather than being packaged to zero.
Morgan Frank, CEO
Not in the filing
stated, not guessed- Company guidance for future periods: no outlook or guidance is printed in this filing, and no previous outlook was provided.
- Year-over-year percentage change for gross margin (basis points), operating loss, net loss, EPS, and nine-month line items: not printed.
- Prior-quarter (Q2 2026) revenue, gross margin, operating loss, net loss, and EPS: not printed.
- Quarterly operating, investing and financing cash flows for Q3 2026: not printed; only nine-month cash flows are given.
- Ultramist system revenue in dollars: not printed; only unit counts and applicator revenue are given.
- Revenue split by product line other than Ultramist applicator revenue: not printed.
- Prior-period balance sheet at September 30, 2025: not printed; the balance sheet compares only to December 31, 2025.
- Prior-year Q3 2025 cash balance and Q3 2025 cash flow detail: not printed as a quarterly figure.
- Change in Ultramist systems sold on a percentage basis: not printed.
- Change in cash balance on a year-over-year basis: not printed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.